Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

NCT ID: NCT00330876

Last Updated: 2010-03-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

545 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was an open-label study of 60 weeks duration in elderly patients (≥65 years) with primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in study NK-104-306 and who met the inclusion/exclusion criteria. Patients who qualified started open-label treatment with pitavastatin 2 mg QD. The dose of pitavastatin could be increased to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain their LDL-C target.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pitavastatin 2 mg QD

Pitavastatin 2 mg once daily

Group Type EXPERIMENTAL

Pitavastatin

Intervention Type DRUG

Pitavastatin 4 mg QD

Pitavastatin 4 mg once daily

Group Type EXPERIMENTAL

Pitavastatin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pitavastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than or equal to 65 years of age
* Primary hypercholesterolemia
* Combined dyslipidemia
* Completed study NK-104-306 (NCT00257686)

Exclusion Criteria

* Failed to complete study NK-104-306(NCT00257686)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kowa Research Europe

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kowa Research Europe

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dragos Budinski, MD

Role: STUDY_DIRECTOR

Medical Director

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Copenhagen University Hospital

Copenhagen, , Denmark

Site Status

Medical Center

Copenhagen, , Denmark

Site Status

CCBR A/S

Vejle, , Denmark

Site Status

Kardiologische Gemeinschaftspraxis Prof. Reifart

Bad Soden/Taunus, , Germany

Site Status

Praxis Dr. Boenninghoff

Beckum, , Germany

Site Status

Klinische Forschung Berlin Mitte

Berlin, , Germany

Site Status

GWT-TUK GmbH, Zentrum fur Klinische Studien

Dresden, , Germany

Site Status

Gemeinschaftspraxis Dr. Krause, Th. Menke

Goch, , Germany

Site Status

Klinische Forschung Hamburg

Hamburg, , Germany

Site Status

Innere Medizin I/Medizinische Klinik

Heidelberg, , Germany

Site Status

Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl

Lampertheim, , Germany

Site Status

ZET-Studien GmbH Leipzig

Leipzig, , Germany

Site Status

Internistische Gemeinschaftspraxis

Mainz, , Germany

Site Status

Praxis Dr. Wachter

Mannheim, , Germany

Site Status

Gemeinschaftspraxis Melcherstaette

Melcherstaette, , Germany

Site Status

Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler

Messkirch, , Germany

Site Status

Praxisgemeinschaft im Kleinen Biergrund

Offenbach/M, , Germany

Site Status

Gemeinschaftspraxis Drs. Mockesch

Weinheim, , Germany

Site Status

Intermed Institud Fur Klinische Forschung und Arzn

Wiesbaden, , Germany

Site Status

Gemeinschaftspraxis Dr. Emden, Frank Drewes

Worpswede, , Germany

Site Status

Department of Internal Medicine, Soroka Medical Center

Beersheva, , Israel

Site Status

Department of Internal Medicine A, Rambal Medical Center

Haifa, , Israel

Site Status

Department of Internal Medicine, Wolfson Medical Center

Holon, , Israel

Site Status

Center for Research, Hadassah University Hospital

Jerusalem Ein Kerem, , Israel

Site Status

Meir Hospital

Kfar Saba, , Israel

Site Status

Department of Medicine, Hadassah Medical Center

Mount Scopus Jerusalem, , Israel

Site Status

Department of Internal Medicine, Rivka Sieff Medical Center

Safed, , Israel

Site Status

Institute of Metabolic Diseases

Tel Aviv, , Israel

Site Status

Institute of Lipid & Atherosclerosis Research

Tel Litwinsky, , Israel

Site Status

Andromed Breda

Breda, , Netherlands

Site Status

Andromed Noord

Groningen, , Netherlands

Site Status

Vasculair Onderzoek Centrum Hoorn

Hoorn, , Netherlands

Site Status

Andromed Leiden

Leiden, , Netherlands

Site Status

Andromed Nijmegen

Nijmegen, , Netherlands

Site Status

Andromed Rotterdam

Rotterdam, , Netherlands

Site Status

Albert Schweitzer Ziekenhuis

Sliedrecht, , Netherlands

Site Status

Rivierenland Tiel

Tiel, , Netherlands

Site Status

Andromed Oost

Velp, , Netherlands

Site Status

Andromed Zoetermeer

Zoetermeer, , Netherlands

Site Status

Oldfield Surgery

Bath, , United Kingdom

Site Status

St James's Surgery

Bath, , United Kingdom

Site Status

The Pulteney Practice

Bath, , United Kingdom

Site Status

Birmingham Clinical Research Centre

Birmingham, , United Kingdom

Site Status

Stonehill Medical Center

Bolton, , United Kingdom

Site Status

Chorley Clinical Research Centre

Chorley, , United Kingdom

Site Status

Saltash Health Center

Cornwall, , United Kingdom

Site Status

Gomersal Lane Surgery

Dronfield, , United Kingdom

Site Status

Townhead Research

Irvine, , United Kingdom

Site Status

Crosby Clinical Research Centre

Liverpool, , United Kingdom

Site Status

The Symons Medical Center

Maidenhead, , United Kingdom

Site Status

Manchester Clinical Research Centre

Manchester, , United Kingdom

Site Status

Greenwood Medical Center

Nottingham, , United Kingdom

Site Status

Reading Clinical Research Centre

Reading, , United Kingdom

Site Status

Elm Lane Surgery

Sheffield, , United Kingdom

Site Status

Brook Lane Surgery

Southampton, , United Kingdom

Site Status

Bradford Road Medical Center

Wiltshire, , United Kingdom

Site Status

Rowden Medical Partnership

Wiltshire, , United Kingdom

Site Status

The Porch Surgery

Wiltshire, , United Kingdom

Site Status

The Burns Medical Practice

Yorkshire, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark Germany Israel Netherlands United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NK-104-308EU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.